KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Buildings (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Buildings for 16 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Buildings rose 18.24% year-over-year to $2.3 billion, compared with a TTM value of $2.3 billion through Dec 2025, up 18.24%, and an annual FY2025 reading of $2.3 billion, up 18.24% over the prior year.
  • Buildings was $2.3 billion for Q4 2025 at Teva Pharmaceutical Industries, up from $2.0 billion in the prior quarter.
  • Across five years, Buildings topped out at $2.6 billion in Q4 2021 and bottomed at $2.0 billion in Q4 2024.
  • Average Buildings over 5 years is $2.4 billion, with a median of $2.5 billion recorded in 2022.
  • The sharpest move saw Buildings fell 20.9% in 2024, then increased 18.24% in 2025.
  • Year by year, Buildings stood at $2.6 billion in 2021, then fell by 4.09% to $2.5 billion in 2022, then grew by 1.02% to $2.5 billion in 2023, then fell by 20.9% to $2.0 billion in 2024, then grew by 18.24% to $2.3 billion in 2025.
  • Business Quant data shows Buildings for TEVA at $2.3 billion in Q4 2025, $2.0 billion in Q4 2024, and $2.5 billion in Q4 2023.